Research Paper: PDF OnlyNatural inhibitors of blood coagulation and fibrinolysis in patients with lupus anticoagulantKordich, L. C.; Forastiero, R. R.; Basilotta, E.; Porterie, P.; Carreras, L. O.Author Information L. C. Kordich, E. Basilotta and P. Porterie are with the Department of Biological Chemistry, School of Exact and Natural Sciences, and R. R. Forastiero and L. O. Carreras are with the Haemostasis and Thrombosis Section, Division of Haematology, Hospital de Clinicas, University of Buenos Aires, Argentina. Blood Coagulation & Fibrinolysis: December 1992 - Volume 3 - Issue 6 - p 765-772 Buy Abstract We studied the natural inhibitors (NI) of blood coagulation and fibrinolysis in 50 patients with lupus anticoagulant (LA), in order to identify possible alterations of these NI, that could favour thrombotic manifestations. We found no statistically significant difference in antithrombin III, protein C and α2-antiplasmin between controls and patients with LA, irrespective of their clinical manifestations. We found an increase of plasminogen activator inhibitor (PAI, P < 0.001) and a decrease of free protein S (PS1, P < 0.001) and total protein S (PSt, 0.01 < P < 0.05) in the patients with LA when compared with the control group. We found no difference in the levels of NI between patients with thrombosis (n = 19) and without thrombosis (n = 31) nor between patients with (n = 25) or without thrombosis and/or foetal loss (n = 25). In contrast, we observed a decrease of PSf in women with foetal loss (n = 10) as compared with women without foetal loss (n = 22, 0.01 < P < 0.05) and a decrease of PS, when comparing 19 patients with systemic lupus erythematosus (SLE) with 31 patients without SLE (0.01 < P < 0.05). These findings show that the patients with LA had several abnormalities in the NI system, but there was no significant association between levels of PAI, PSf, PSt and a history of thrombosis. © Lippincott-Raven Publishers.